Vitrafy Life Sciences Ltd (ASX: VFY) Share Price and News

Ms Munnings has experience as a senior executive at health and services companies. Kate created Virtus Ventures, which included collaborations between Virtus Health and a range of biotech start-ups, to undertake translational research, commercialize technology and obtain innovation grants. Kate was previously a partner at Corrs Chambers Westgarth, and Baker McKenzie. She is a member of the Risk Committee.

Mr Webber has industry and public markets experience, having spent more than 20 years in corporate finance at Australian stockbrokers, focusing on developing, funding and executing strategies for mid-to-small cap listed companies (including IPO experience). He is the Chair of the Risk Committee.

Mr Farrell is the Managing Director of AdNED Pty Ltd, non-executive director of both Ena Respiratory Pty Ltd and Axelia Oncology Pty Ltd, a member of the Walter and Eliza Hall Institute of Medical Research Board Commercialisation Committee, a member of the Scientific and Industry Advisory Committee of the Australian Research Council Centre for Cryoelectron Microscopy of Membrane Proteins and a member of the Investment Committee for the CUREAtor Plus.Dementia and Cognitive Decline Grants which is funded by the Australian Medical Research Future Fund. Leigh was previously Head of Health Security Systems Australia, a Division of DMTC Ltd, Senior Vice President, Commercial of Certara USA, Inc. where he was responsible for Asia Pacific Commercial. Prior to this, he was Chairman and COO of d3 Medicine LLC, which was acquired by Certara USA, Inc. Prior to these appointments, Leigh was Vice President of Global Business Development at Biota Pharmaceuticals, Associate Director GBS Venture Partners, Research Manager Johnson & Johnson Research and CEO of Gene Shears Pty Ltd. He is a Member of the Risk Committee.

Dr Joughin brings pharmaceutical industry experience in both Australia and the United States and has directed both in and out licensing of products, growth and commercialization strategies across small to large cap companies. Jeannie's early career included roles across several therapeutic areas including oncology, cardiovascular and neurology. She spent several years in product launch and commercialisation for Bristol-Myers Squibb, Marketing Manager for Mayne Pharma before moving to CSL Biotherapies (now Sequiris) as Director, Pharmaceuticals Marketing & Business Development in 2005. In 2015, Jeannie took on the role of Executive Vice President and Chief Commercial Officer of the US based Enable Injections Inc. with direct responsibility for the growth of its worldwide business and its capital raises. Returning to Australia, Jeannie served as non-executive director on 2 private company boards and joined the venture capital fund, OneVentures, in 2021. She currently serves as a non-executive director on various private company boards. She is a member of the Risk Committee.

Mr Owens has expertise in intellectual property development. He has played a role in initiating Vitrafy's technological innovations, product development and enterprise grade software, securing collaboration agreements, grant funding and securing supporting patent protection.

-

-

-